Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature
- PMID: 17296816
- DOI: 10.1634/theoncologist.12-2-201
Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature
Abstract
Worldwide, approximately 1.3 billion individuals are current smokers, and smoking is the second major cause of death. Currently, lung cancer is the most common type of cancer in Europe, and the third in the U.S. Until now, cytotoxic chemotherapy has had a limited impact on survival in metastatic non-small cell lung cancer (NSCLC). The central role of epidermal growth factor (EGF) and its receptor (EGFR) in lung carcinogenesis is well recognized. Genetic polymorphisms are variants in individual genomes that may be responsible for different functional molecular roles and contribute to variability in drug pharmacokinetic and pharmacodynamic processes. Herein, we review the literature on EGF and EGFR functions and activities, particularly the current role of their functional polymorphisms as related to NSCLC.
Similar articles
-
Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.Expert Opin Pharmacother. 2010 Oct;11(14):2363-89. doi: 10.1517/14656566.2010.498581. Expert Opin Pharmacother. 2010. PMID: 20586711 Review.
-
Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.Oncogene. 2009 Aug;28 Suppl 1:S14-23. doi: 10.1038/onc.2009.197. Oncogene. 2009. PMID: 19680292 Review.
-
Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4606-12. doi: 10.1158/1078-0432.CCR-07-0332. Clin Cancer Res. 2007. PMID: 17671150 Review.
-
First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?Curr Opin Oncol. 2011 Mar;23(2):131-2. doi: 10.1097/CCO.0b013e328341ee26. Curr Opin Oncol. 2011. PMID: 21307676 No abstract available.
-
Epidermal growth factor receptor mutations in lung cancer.Nat Rev Cancer. 2007 Mar;7(3):169-81. doi: 10.1038/nrc2088. Nat Rev Cancer. 2007. PMID: 17318210 Review.
Cited by
-
Tyrosine kinase domain mutations of EGFR gene in head and neck squamous cell carcinoma.Onco Targets Ther. 2017 Mar 13;10:1527-1533. doi: 10.2147/OTT.S132187. eCollection 2017. Onco Targets Ther. 2017. PMID: 28352186 Free PMC article.
-
Rheumatoid arthritis is associated with rs17337023 polymorphism and increased serum level of the EGFR protein.PLoS One. 2017 Jul 11;12(7):e0180604. doi: 10.1371/journal.pone.0180604. eCollection 2017. PLoS One. 2017. PMID: 28700691 Free PMC article.
-
EGFR-targeted therapies in lung cancer: predictors of response and toxicity.Pharmacogenomics. 2009 Jan;10(1):59-68. doi: 10.2217/14622416.10.1.59. Pharmacogenomics. 2009. PMID: 19102716 Free PMC article. Review.
-
The Association between Epidermal Growth Factor Receptor (EGFR) Gene Polymorphisms and Lung Cancer Risk.Biomolecules. 2018 Jul 13;8(3):53. doi: 10.3390/biom8030053. Biomolecules. 2018. PMID: 30011810 Free PMC article.
-
The effect of 5'untranslated region polymorphism in EGF gene, rs4444903, on colorectal cancer.Gastroenterol Hepatol Bed Bench. 2013 Summer;6(3):129-35. Gastroenterol Hepatol Bed Bench. 2013. PMID: 24834259 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous